Haixiang Pharmaceutical (002099.SZ) released semi-annual results, with a net loss of 64.038 million yuan to mother

According to Zhitong Finance App News, Haixiang Pharmaceutical (002099.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved operating income of 1,023 million yuan, an increase of 10.56% over the previous year; achieved a net loss attributable to shareholders of listed companies of 640.38 million yuan, which changed from profit to loss over the previous year; net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss of 124 million yuan, year-on-year from profit to loss; basic earnings per share -0.04 yuan.

In the first half of 2026, the company closely focused on the annual business goals and solidly promoted various tasks such as R&D, production, sales, registration and quality, and the overall operation remained stable. The company stepped up BD expansion efforts, actively participated in various pharmaceutical and dye exhibitions in the US, Shanghai, Japan, Bangladesh, etc., continued to develop new customers and new projects, and prepare projects for future development.